/Agilent%20Technologies%20Inc_%20phone%20and%20website-by%20T_Schneider%20via%20Shutterstock.jpg)
Agilent Technologies, Inc. (A), headquartered in Santa Clara, California, provides application focused solutions to the life sciences, diagnostics, and applied chemical markets. Valued at $34 billion by market cap, the company offers electronic and bio-analytical measurement, semiconductor, and board testing. The global leader in analytical and clinical laboratory technologies is expected to announce its fiscal second-quarter earnings for 2026 in the near future.
Ahead of the event, analysts expect A to report a profit of $1.41 per share on a diluted basis, up 7.6% from $1.31 per share in the year-ago quarter. The company beat or matched the consensus estimates in three of the last four quarters while missing the forecast on another occasion.
For the full year, analysts expect A to report EPS of $5.95, up 6.4% from $5.59 in fiscal 2025. Its EPS is expected to rise 10.1% year over year to $6.55 in fiscal 2027.
A stock has underperformed the S&P 500 Index’s ($SPX) 32.2% gains over the past 52 weeks, with shares up 9% during this period. However, it outperformed the State Street Health Care Select Sector SPDR ETF’s (XLV) 7.7% gains over the same time frame.
On Feb. 25, A reported its Q1 results, and its shares closed down more than 3% in the following trading session. Its adjusted EPS of $1.36 fell short of Wall Street expectations of $1.37. The company’s revenue was $1.8 billion, meeting Wall Street forecasts. A expects full-year adjusted EPS in the range of $5.90 to $6.04, and revenue ranging from $7.3 billion to $7.5 billion.
Analysts’ consensus opinion on A stock is bullish, with a “Strong Buy” rating overall. Out of 16 analysts covering the stock, 11 advise a “Strong Buy” rating, one suggests a “Moderate Buy,” and four give a “Hold.” A’s average analyst price target is $162.64, indicating an ambitious potential upside of 42.1% from the current levels.
